A Study to Evaluate Food Effect on ONO-5920/YM529 Intermittent Formulation

NCT00965978 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

48

Enrollment

INDUSTRY

Sponsor class

Conditions

Osteoporosis
Osteoporosis, Postmenopausal
Bone Diseases

Interventions

DRUG: ONO-5920 / YM529

Sponsor

Astellas Pharma Inc

Collaborators

[object Object]